Ribonucleic Acid (RNA)-Based Oncolytic Therapy Global Market Report 2025

Description

Ribonucleic acid (RNA)-based oncolytic therapy is a cancer treatment that employs engineered RNA viruses to selectively infect and destroy tumor cells. These viruses replicate within cancer cells, leading to cell death and the release of tumor antigens. This process also activates the immune system to target remaining cancer cells, enhancing overall anti-tumor effectiveness.

The primary therapy types of ribonucleic acid (RNA)-based oncolytic therapy are messenger RNA (mRNA)-based oncolytic therapy, small interfering RNA (siRNA)-based oncolytic therapy, micro RNA (miRNA)-based oncolytic therapy, and other therapy types. Messenger RNA (mRNA)-based oncolytic therapy involves using synthetic mRNA molecules designed to stimulate the immune system or directly induce tumor cell death, providing a targeted and adaptable approach to cancer treatment. These therapies are administered via intravenous, intratumoral, and other routes, and are applied in breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and other indications. Key end-users include hospitals, cancer research institutes, specialty clinics, and related healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The ribonucleic acid (RNA)-based oncolytic therapy market research report is one of a series of new reports from The Business Research Company that provides ribonucleic acid (RNA)-based oncolytic therapy market statistics, including the ribonucleic acid (RNA)-based oncolytic therapy industry global market size, regional shares, competitors with the ribonucleic acid (RNA)-based oncolytic therapy market share, detailed ribonucleic acid (RNA)-based oncolytic therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the ribonucleic acid (RNA)-based oncolytic therapy industry. This ribonucleic acid (RNA)-based oncolytic therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ribonucleic acid (RNA)-based oncolytic therapy market size has grown rapidly in recent years. It will grow from $1.78 billion in 2024 to $2.12 billion in 2025 at a compound annual growth rate (CAGR) of 18.9%. The growth in the historic period is attributed to the increasing prevalence of cancer, rising investment in healthcare infrastructure, growing awareness of targeted therapies, expansion of clinical trial programs, and higher government funding for oncology research.

The ribonucleic acid (RNA)-based oncolytic therapy market size is expected to see rapid growth in the next few years. It will grow to $4.17 billion in 2029 at a compound annual growth rate (CAGR) of 18.5%. The growth in the forecast period is driven by greater adoption of RNA-based therapies, increased focus on immuno-oncology, rising biotechnology collaborations, expansion of advanced manufacturing facilities, and improved access to precision medicine. Key trends in the forecast period include technological advancements, progress in viral vector design, increased investment in research and development, innovation in delivery systems, and the development of combination therapy approaches.

The increasing adoption of personalized medicine is expected to drive growth in the RNA-based oncolytic therapy market. Personalized medicine involves tailoring medical treatments according to an individual's genetic profile, which enhances treatment effectiveness while minimizing side effects. This approach is being embraced more widely as healthcare providers and institutions recognize its potential to improve patient outcomes through targeted therapies and precise diagnostics. RNA-based oncolytic therapy supports this trend by providing targeted, patient-specific cancer treatments that align with personalized medicine principles. For example, in February 2024, the Personalized Medicine Coalition, a United States-based advocacy organization for tailored treatments, reported that the FDA approved sixteen new personalized therapies for rare disease patients in 2023, a notable increase from six approvals in 2022. Consequently, the growing use of personalized medicine is propelling the RNA-based oncolytic therapy market forward.

Leading companies in the RNA-based oncolytic therapy market are advancing technologies such as synthetic messenger RNA (mRNA) to improve tumor targeting, stimulate immune responses, and achieve more precise and lasting cancer treatment results. Synthetic mRNA technology is a biotech method that creates and delivers artificial mRNA sequences to instruct cells to produce specific therapeutic proteins to treat diseases, including cancer. For example, in June 2024, CSPC Pharmaceutical Group Limited, a pharmaceutical company based in China, received regulatory clearance to begin clinical trials of SYS6020, a synthetic mRNA-based cancer cell therapy. This milestone marks a significant step in China's mRNA therapeutic field. SYS6020 uses mRNA-lipid nanoparticle technology to selectively attack and destroy myeloma cancer cells with minimal side effects, and it shows promise for treating certain autoimmune disorders.

In June 2023, Charles River Laboratories International, Inc., a US contract research organization, formed a strategic partnership with Curigin Co., Ltd. to develop oncolytic RNA interference (RNAi) gene therapies. The collaboration aims to accelerate the development and production of Curigin's RNAi-based oncolytic gene therapies by utilizing Charles River's contract development and manufacturing expertise to support both preclinical and clinical studies. Curigin Co., Ltd. is a South Korea-based biotech firm specializing in RNAi oncolytic gene therapies for cancer treatment.

Major players in the ribonucleic acid (RNA)-based oncolytic therapy market are AstraZeneca PLC, Moderna Inc., BioNTech SE, Gritstone Bio Inc., Orna Therapeutics Inc., Strand Therapeutics Inc., Oncolytics Biotech Inc., Anima Biotech Inc., eTheRNA immunotherapies NV, Vyriad Inc., Haya Therapeutics Inc., Virogin Biotech Inc., Providence Therapeutics Holdings Inc., Sirnaomics Inc., Humane Genomics Inc., Replicate Bioscience Inc., Abogen Biosciences Inc., Chimeron Bio Inc., Aro Biotherapeutics Inc., TransCode Therapeutics Inc.

North America was the largest region in the ribonucleic acid (RNA)-based oncolytic therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ribonucleic acid (RNA)-based oncolytic therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ribonucleic acid (RNA)-based oncolytic therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ribonucleic acid (RNA)-based oncolytic therapy market includes revenues earned by entities through services such as clinical trials, tumor targeting, immune monitoring, patient support, and treatment administration. The market value includes the value of related goods sold by the service provider or included within the service offering. The ribonucleic acid (RNA)-based oncolytic therapy market also includes sales of RNA oncolytic viruses, viral vectors, delivery systems, formulations, and diagnostic kits. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ribonucleic Acid (RNA)-Based Oncolytic Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ribonucleic acid (rna)-based oncolytic therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ribonucleic acid (rna)-based oncolytic therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ribonucleic acid (rna)-based oncolytic therapy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Therapy Type: Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy; Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy; Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy; Other Therapy Types
2) By Route Of Administration: Intravenous; Intratumoral; Other Route Of Administrations
3) By Application: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Other Applications
4) By End-User: Hospitals; Cancer Research Institutes; Specialty Clinics; Other End-Users
Subsegments:
1) By Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy: Self-Amplifying mRNA (saRNA); Non-Replicating mRNA; Circular RNA (circRNA)-Based mRNA therapy
2) By Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy: Chemically Modified siRNA; Nanoparticle-Delivered siRNA; Conjugated siRNA
3) By Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy: miRNA Mimics; miRNA Inhibitors (Antagomirs); miRNA Aponges Or Decoys
4) By Other Therapy Types: Long Non-Coding RNA (lncRNA)-Based Therapies; Short Hairpin RNA (shRNA)-Based Therapies; Aptamer-RNA Based Oncolytic Agents
Companies Mentioned: AstraZeneca PLC; Moderna Inc.; BioNTech SE; Gritstone Bio Inc.; Orna Therapeutics Inc.; Strand Therapeutics Inc.; Oncolytics Biotech Inc.; Anima Biotech Inc.; eTheRNA immunotherapies NV; Vyriad Inc.; Haya Therapeutics Inc.; Virogin Biotech Inc.; Providence Therapeutics Holdings Inc.; Sirnaomics Inc.; Humane Genomics Inc.; Replicate Bioscience Inc.; Abogen Biosciences Inc.; Chimeron Bio Inc.; Aro Biotherapeutics Inc.; TransCode Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r38627

1. Executive Summary

2. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Characteristics

3. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Trends And Strategies

4. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Growth Analysis And Strategic Analysis Framework

5.1. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Growth Rate Analysis
5.4. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Total Addressable Market (TAM)

6. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Segmentation

6.1. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy
Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy
Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy
Other Therapy Types
6.2. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous
Intratumoral
Other Route Of Administrations
6.3. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Other Applications
6.4. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Cancer Research Institutes
Specialty Clinics
Other End-Users
6.5. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Sub-Segmentation Of Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Self-Amplifying mRNA (saRNA)
Non-Replicating mRNA
Circular RNA (circRNA)-Based mRNA Therapy
6.6. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Sub-Segmentation Of Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemically Modified siRNA
Nanoparticle-Delivered siRNA
Conjugated siRNA
6.7. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Sub-Segmentation Of Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
miRNA Mimics
miRNA Inhibitors (Antagomirs)
miRNA Sponges Or Decoys
6.8. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Sub-Segmentation Of Other Therapy Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Long Non-Coding RNA (lncRNA)-Based Therapies
Short Hairpin RNA (shRNA)-Based Therapies
Aptamer-RNA Based Oncolytic Agents

7. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Regional And Country Analysis

7.1. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

8.1. Asia-Pacific Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

9.1. China Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
9.2. China Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

10.1. India Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

11.1. Japan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
11.2. Japan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

12.1. Australia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

13.1. Indonesia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

14.1. South Korea Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
14.2. South Korea Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

15.1. Western Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
15.2. Western Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

16.1. UK Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

17.1. Germany Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

18.1. France Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

19.1. Italy Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

20.1. Spain Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

21.1. Eastern Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
21.2. Eastern Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

22.1. Russia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

23.1. North America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
23.2. North America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

24.1. USA Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
24.2. USA Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

25.1. Canada Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
25.2. Canada Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

26.1. South America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
26.2. South America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

27.1. Brazil Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

28.1. Middle East Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
28.2. Middle East Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

29.1. Africa Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview
29.2. Africa Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Competitive Landscape And Company Profiles

30.1. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Competitive Landscape
30.2. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Company Profiles
- 30.2.1. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. BioNTech SE Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Gritstone Bio Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Orna Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Other Major And Innovative Companies

31.1. Strand Therapeutics Inc.
31.2. Oncolytics Biotech Inc.
31.3. Anima Biotech Inc.
31.4. eTheRNA immunotherapies NV
31.5. Vyriad Inc.
31.6. Haya Therapeutics Inc.
31.7. Virogin Biotech Inc.
31.8. Providence Therapeutics Holdings Inc.
31.9. Sirnaomics Inc.
31.10. Humane Genomics Inc.
31.11. Replicate Bioscience Inc.
31.12. Abogen Biosciences Inc.
31.13. Chimeron Bio Inc.
31.14. Aro Biotherapeutics Inc.
31.15. TransCode Therapeutics Inc.

32. Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

34. Recent Developments In The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

35. Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market High Potential Countries, Segments and Strategies

35.1 Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market In 2029 - Countries Offering Most New Opportunities
35.2 Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market In 2029 - Segments Offering Most New Opportunities
35.3 Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer